Inhibition of the trigemino-vascular system with 5-ht1d agonist drugs: Selectively targeting additional sites of action

European Neurology

Volumn 36, Issue , 1996, Pages 13-18

  Martin, Graeme R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

311C90; Clinical pharmacology; Mode of action; Oral bioavailability; Trigemino vascular system

Indexed keywords

SEROTONIN AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN STEM; DRUG DEVELOPMENT; HUMAN; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRIGEMINAL NERVE; TRIGEMINAL NUCLEUS; VASODILATATION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CEREBROVASCULAR CIRCULATION; HUMANS; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; SEROTONIN AGONISTS; TRIGEMINAL NERVE; TRYPTAMINES;

EID: 0030067627     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000119098     Document Type: Article

References (22)

1. McNaughton FL: The innervation of the intracranial blood vessels and the dural sinuses. In: Cobb S. Frantz AM. Penfield W, Riley HA (eds) The Circulation of the Brain and Spinal Cord. New York. Hafner Publishing Co. Inc. 1966:178-200.
2. Moskowitz MA, Reinhard JF, Romero J, Melamed E, Pcttibone DJ: Ncurotransmitlers and the 5lh cranial nerve: is there a relation to the headache phase of migraine? Lancet 1979: 2:883-885.
3. Lance JW: Mechanism and management of headache (5th Edition). London, Butterworth Scientific. 1993.
4. Humphrey PPA, Goadsby PJ: The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994;14:401-410.
5. Martin GR: Central and peripheral actions of 5-HT„, agonists used in the acute treatment of migraine. In: F. Clifford Rose (ed) Leeds Castle Migraine Workshop. Elsevier Science B.V. 1996: in press.
6. Humphrey PPA, Feniuk W, Marriot JS, Tanner RJN, Jackson MR, Tucker ML: Pre-clinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991;31:282-290.
7. Lambert GA, Goadsby PJ, Zagami AS, Duckworth JW: Comparative effects of stimulation of the trigeminal ganglion and the superior sagittal sinus in cerebral blood flow and evoked potentials in the cat. Brain Res 1988; 453:143-149.
8. Kaube H, Hoskin KL, Goadsby PJ: Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109:788-792.
9. Taylor DC, Lynch J, Leahy DE: Models for intestinal permeability of drugs. In: Drug delivery to the gastrointestinal tract. Hardy JG. Davies SS. Wilson CG (eds.) Ellis-Horwood 1989. pp 134-145.
10. Sharman DF: Drugs and other pharmacologically active compounds. In: Data for Biochemical Research. Dawson RMC. Elliot DC. Elliot WH. Jones KM (eds). Oxford University Press 1969. pp 405 -421.
11. Hill AP, Hyde RM, Robertson AD, Woollard PM, Glen RC, Martin GR: Oral delivery of 5-HT, receptor agonists: towards the discovery of 3I1C90, a novel anti-migraine agent. Headache 1994:34:308.
12. Buzzi MG, Carter WB, Shimizu T, Heath H, Moskowitz MA: Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Ncuropharmacol 1991;30:1193-1200.
13. Goadsby PJ, Edvinsson L: The trigeminovas-cular system and migraine: Studies characteris-ing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993: 33:48-56.
14. Goadsby PJ, Edvinsson L: Peripheral and central trigeminovascular activation in cat is blocked by the serotonin(5-HT)-ID receptor agonist 311C90. Headache 1994; 34:394-399.
15. Moskowitz MA: Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992:13: 307-311.
16. Humphrey PPA, Feniuk W: Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991:12:444-445.
17. Goadsby PJ, Hoskin KL: Trigeminal neuronal activity is inhibited by intravenous administration of 31IC90 in the cat. Cephalalgia 1995:15 (suppl 14): 106.
18. Knight YE. Goadsby PJ: Central nervous system distribution of [H]3I IC90 in cat. Cephalalgia 1995:15(suppl 14):214.
19. Mills A, Rhodes P, Martin GR: |H|3IIC90 binding sites in cat brain stem: implications for migraine treatment. Cephalalgia 1995:15 (suppl 14): 116.
20. Mills A, Martin GR: Labelling of cat brainstem sections with |T1|31 IC90and the5-HT, receptor ligand |H|BRL43694. Cephalalgia 1995: 15(suppl 14):213.
21. Seabcr E, On N, Phillips S, Churchus R, Posncr J, Rolan P: The tolerability and pharmacokinetic of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996:41:141-147.
22. Lacey L.F, Hussey F.K, Fowler PA: The single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995: 47:543-548.